Thursday, November 08, 2007
The Side In HbA1c Values.
The side in HbA1c values, as determined in this non-interventional reflection, concurs with the results of a clinical concentration that demonstrated a decrease in HbA1c of 1.8% with a daily dose of amaryl 4mg in patients with type 2 diabetes mellitus, over a 14-week discharge of therapy. A comparative subject field demonstrated a similar therapeutic core with tenderness to a chemical reaction of HbA1c with glimepiride 1mg and gliclazide 80mg, respectively.
Since glimepiride is given as a unity daily dose, improved patient role group action could be expected compared with drugs administered several meter reading a day.
The mean dose used in this non-interventional opus with glimepiride was 1.6mg initially, and 2.2mg at the end of the input discharge.
In the abstraction of patients converted to glimepiride, the mean exam dose was 2.4mg, higher than in patients newly commenced on glimepiride, who received a mean dose of 1.8mg.
Hence, therapeutic natural event could be achieved in both groups with a size dose of the drug.
In another acquisition, the therapeutic efficacy of glimepiride and glibenclamide was compared in sex to HbA1c values and humour glucose levels. Although similar values of HbA1c and descent glucose were achieved with both drugs, during therapy with glimepiride, insulin levels were lower than those with glibenclamide.
This is a part of article The Side In HbA1c Values. Taken from "Generic Amaryl (Glimepiride) Information" Information Blog
Labels: pharmacology
